Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jitters Over Innovative Drug Pricing System Intensify In Korea As FTA Revision Deadline Nears

Executive Summary

Concerns are brewing in South Korea as a deadline to revise the global innovative drug pricing system nears as part of the revised FTA with the US. One lawmaker has asked the government to cautiously negotiate with the US over any revisions to protect the domestic pharma industry and financial status of the national health insurance scheme.
Advertisement

Related Content

US, Korea FTA Talks To Improve Pro-Innovation Pricing System

Topics

Advertisement
UsernamePublicRestriction

Register

PS124117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel